Updated
PulmonxLUNG · Healthcare
$2.56+0.00%
Market cap$111M
IndustryMedical Devices
Pulmonx (LUNG) Revenue breakdown
By region, United States is the largest at 63% of fiscal 2025 revenue, growing 93% a year over 7 years.
Revenue by region
Fiscal years, as Pulmonx reports them in its 10-K filings; fiscal 2025 total $90M.
| Regions | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| United States | $563,000 | $11M | $16M | $25M | $32M | $46M | $56M | $57M | 63% |
| Europe, Middle-East and Africa (“EMEA”) | $16M | $18M | $14M | $20M | $18M | $19M | $22M | $27M | 30% |
| Asia Pacific | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $6M | 7% |
| Other International | $151,000 | $300,000 | $49,000 | $128,000 | $155,000 | $399,000 | $556,000 | $260,000 | 0% |
Questions about Pulmonx
Where does Pulmonx make its money?
In fiscal 2025, by region: United States $57M, Europe, Middle-East and Africa (“EMEA”) $27M, Asia Pacific $6M, Other International $260,000.
From Pulmonx's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.